MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer.

已完结 10 由立秋发布于 2024/4/20 19:56:19

DOI:10.1016/j.celrep.2023.113221
作者：Preston D Crowell, Jenna M Giafaglione, Anthony E Jones, Nicholas M Nunley, Takao Hashimoto, Amelie M L Delcourt, Anton Petcherski, Raag Agrawal, Matthew J Bernard, Johnny A Diaz, Kylie Y Heering, Rong Rong Huang, Jin-Yih Low, Nedas Matulionis, Nora M Navone, Huihui Ye, Amina Zoubeidi, Heather R Christofk, Matthew B Rettig, Robert E Reiter, Michael C Haffner, Paul C Boutros, Orian S Shirihai, Ajit S Divakaruni, Andrew S Goldstein
文献类型：期刊论文
补充材料：只需要正文

Elsevier

Abstract：Advanced prostate cancers are treated with therapies targeting the androgen receptor (AR) signaling pathway. While many tumors initially respond to AR inhibition, nearly all develop resistan

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:WileyEpigenetic cues regulating airway development in human lung organoids: Polycomb repressive complex 2 and altered chromatin accessibility determine cell fate